Compare · IVVD vs RVMD
IVVD vs RVMD
Side-by-side comparison of Invivyd Inc. (IVVD) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IVVD and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $43.68B, about 188.6x IVVD ($231.5M).
- Over the past year, IVVD is down 44.6% and RVMD is up 337.8% - RVMD leads by 382.4 points.
- RVMD has been more active in the news (15 items in the past 4 weeks vs 13 for IVVD).
- RVMD has more recent analyst coverage (25 ratings vs 7 for IVVD).
- Company
- Invivyd Inc.
- Revolution Medicines Inc.
- Price
- $0.79+1.31%
- $203.82+0.25%
- Market cap
- $231.5M
- $43.68B
- 1M return
- +7.54%
- -0.69%
- 1Y return
- -44.64%
- +337.76%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2020
- News (4w)
- 13
- 15
- Recent ratings
- 7
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest IVVD
- Invivyd to Participate in Upcoming September Investor Conferences
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 4 filed by Director Sheffield Ian
- SEC Form 3 filed by new insider Sheffield Ian
- SEC Form 4 filed by Chief Executive Officer Elia Marc
- Invivyd Inc. filed SEC Form 8-K: Leadership Update, Other Events
- Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY
- Chief Financial Officer Duke William E. converted options into 102,000 shares and sold $31,671 worth of shares (40,780 units at $0.78) as part of a pre-agreed trading plan, increasing direct ownership by 57% to 168,937 units (SEC Form 4) (for withholding tax)
- Chief Human Resources Officer Green Julie converted options into 102,000 shares and sold $31,671 worth of shares (40,780 units at $0.78) as part of a pre-agreed trading plan, increasing direct ownership by 57% to 168,937 units (SEC Form 4) to satisfy tax liability
- Chief Scientific Officer Allen Robert D. Iii sold $29,296 worth of shares (37,722 units at $0.78) as part of a pre-agreed trading plan and converted options into 102,000 shares, increasing direct ownership by 56% to 178,765 units (SEC Form 4) to satisfy withholding tax
Latest RVMD
- SEC Form 144 filed by Revolution Medicines Inc.
- Director Kim Lorence H. sold $3,585,837 worth of shares (17,090 units at $209.82) as part of a pre-agreed trading plan (SEC Form 4)
- Morgan Stanley initiated coverage on Revolution Medicines with a new price target
- New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
- Director Kim Lorence H. sold $11,381,288 worth of shares (56,000 units at $203.24) as part of a pre-agreed trading plan (SEC Form 4)
- Revolution Medicines Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- FDA Approval for RASONQUE issued to REVOLUTION MEDICINES INC
- Bloomberg 500 (B500) Index Adds Ten Securities Following September Reconstitution
- Revolution Medicines Inc. filed SEC Form 8-K: Other Events
- U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer